Journal Mobile Options
Table of Contents
Vol. 77, No. 2, 2003
Issue release date: February 2003
Neuroendocrinology 2003;77:125–131

Effects of Galanin-Like Peptide on Food Intake and the Hypothalamo-Pituitary-Thyroid Axis

Seth A. · Stanley S. · Dhillo W. · Murphy K. · Ghatei M. · Bloom S.
Division of Metabolic Medicine, Faculty of Medicine, Imperial College of Science Technology and Medicine, Hammersmith Campus, London, UK

Individual Users: Register with Karger Login Information

Please create your User ID & Password

Contact Information

I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in


Galanin-like peptide (GALP) is a novel hypothalamic peptide synthesised in neurons in the arcuate nucleus which project to the paraventricular nucleus (PVN). GALP has recently been identified as an orexigenic peptide. In this study we aimed to further characterise the hypothalamic action of this peptide in energy homeostasis. Firstly, we investigated the orexigenic effect of GALP in the PVN and compared its effects with galanin and galanin 2–29. Secondly, we examined the effect of PVN administration of GALP and galanin on circulating thyroid-stimulating hormone (TSH). PVN administration of GALP significantly increased the food intake of satiated rats 1 h after administration at doses of 0.3, 1 and 3 nmol. In comparison with paraventricular administration of galanin, GALP was a more potent orexigen, whereas galanin 2–29, the relatively selective GAL R2 agonist, had no effect on food intake. Both GALP and galanin administration (1 nmol) into the PVN significantly decreased the level of circulating TSH. To investigate the mechanism of these effects, we examined the effect of GALP and galanin application on neuropeptide release from hypothalamic explants in vitro. GALP peptide (100 nM) stimulated the release of the orexigenic peptide neuropeptide Y from hypothalamic explants and decreased the release of the anorectic peptide cocaine-and-amphetamine-regulated transcript, whereas galanin (100 nM) peptide had no significant effect on the release of either peptide. Both GALP (100 nM) and galanin (100 nM) inhibited the release thyrotrophin-releasing hormone. These data suggest that in the PVN, GALP may play a role in energy homeostasis by stimulating food intake and suppressing TSH release.

Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.


  1. Ohtaki T, Kumano S, Ishibashi Y, Ogi K, Matsui H, Harada M, Kitada C, Kurokawa T, Onda H, Fujino M: Isolation and cDNA cloning of a novel galanin-like peptide from porcine hypothalamus. J Biol Chem 1999;274:37041–37045.
  2. Takatsu Y, Matsumoto H, Ohtaki T, Kumano S, Kitada C, Onda H, Nishimura O, Fujino M: Distribution of galanin-like peptide in the rat brain. Endocrinology 2001;142:1626–1634.
  3. Matsumoto Y, Watanabe T, Adachi Y, Itoh T, Ohtaki T, Onda H, Kurokawa T, Nishimura O, Fujino M: Galanin-like peptide stimulates food intake in the rat. Neurosci Lett 2002;322:67–69.
  4. Crawley JN, Austin MC, Fiske SM, Martin B, Consolo S, Berthold M, Langel U, Fisone G, Bartfai T: Activity of centrally administered galanin fragments on stimulation of feeding behavior and on galanin receptor binding in the rat hypothalamus. J Neurosci 1990;10:3695–3700.
  5. Habert-Ortoli E, Amiranoff B, Loquet I, Laburthe M, Mayaux JF: Molecular cloning of a functional human galanin receptor. Proc Natl Acad Sci USA 1994;91:9780–9783.
  6. Smith KE, Walker MW, Artymyshyn R, Bard J, Borowsky B, Tamm JA, Yao WJ, Vaysse PJ, Branchek TA, Gerald C, Jones KA: Cloned human and rat galanin GALR3 receptors. Pharmacology and activation of G-protein inwardly rectifying K+ channels. J Biol Chem 1998;273:23321–23326.
  7. Howard AD, Tan C, Shiao LL, Palyha OC, McKee KK, Weinberg DH, Feighner SD, Cascieri MA, Smith RG, Van Der Ploeg LH, Sullivan KA: Molecular cloning and characterization of a new receptor for galanin. FEBS Lett 1997;405:285–290.

    External Resources

  8. Wang S, Ghibaudi L, Hashemi T, He C, Strader C, Bayne M, Davis H, Hwa JJ: The GalR2 galanin receptor mediates galanin-induced jejunal contraction, but not feeding behavior, in the rat: Differentiation of central and peripheral effects of receptor subtype activation. FEBS Lett 1998;434:277–282.
  9. Freake HC, Oppenheimer JH: Thermogenesis and thyroid function. Annu Rev Nutr 1995;15:263–291.
  10. Fekete C, Kelly J, Mihaly E, Sarkar S, Rand WM, Legradi G, Emerson CH, Lechan RM: Neuropeptide Y has a central inhibitory action on the hypothalamic-pituitary-thyroid axis. Endocrinology 2001;142:2606–2613.
  11. Kim MS, Small CJ, Stanley SA, Morgan DG, Seal LJ, Kong WM, Edwards CM, Abusnana S, Sunter D, Ghatei MA, Bloom SR: The central melanocortin system affects the hypothalamo-pituitary thyroid axis and may mediate the effect of leptin. J Clin Invest 2000;105:1005–1011.
  12. Winokur A, Utiger RD: Thyrotropin-releasing hormone: Regional distribution in rat brain. Science 1974;185:265–267.
  13. Todd JF, Small CJ, Akinsanya KO, Stanley SA, Smith DM, Bloom SR: Galanin is a paracrine inhibitor of gonadotroph function in the female rat. Endocrinology 1998;139:4222–4229.
  14. Kim MS, Rossi M, Abusnana S, Sunter D, Morgan DG, Small CJ, Edwards CM, Heath MM, Stanley SA, Seal LJ, Bhatti JR, Smith DM, Ghatei MA, Bloom SR: Hypothalamic localization of the feeding effect of agouti-related peptide and α-melanocyte-stimulating hormone. Diabetes 2000;49:177–182.
  15. Paxinos G, Watson C: The Rat Brain in Stereotactic Coordinates. San Diego, Academic Press, 1998.
  16. Stanley SA, Small CJ, Kim MS, Heath MM, Seal LJ, Russell SH, Ghatei MA, Bloom SR: Agouti-related peptide stimulates the hypothalamo-pituitary-gonadal axis in vivo and in vitro in male rats. Endocrinology 1999;140:5459–5462.
  17. Allen YS, Adrian TE, Allen JM, Tatemoto K, Crow TJ, Bloom SR, Polak JM: Neuropeptide Y distribution in the rat brain. Science 1983;221:877–879.
  18. Korner J, Chua SC Jr, Williams JA, Leibel RL, Wardlaw SL: Regulation of hypothalamic proopiomelanocortin by leptin in lean and obese rats. Neuroendocrinology 1999;70:377–383.
  19. Murphy KG, Abbott CR, Mahmoudi M, Hunter R, Gardiner JV, Rossi M, Stanley SA, Ghatei MA, Kuhar MJ, Bloom SR: Quantification and synthesis of cocaine- and amphetamine-regulated transcript peptide (79–102)-like immunoreactivity and mRNA in rat tissues. J Endocrinol 2000;166:659–668.
  20. Seal LJ, Small CJ, Dhillo WS, Stanley SA, Abbott CR, Ghatei MA, Bloom SR: PRL-releasing peptide inhibits food intake in male rats via the dorsomedial hypothalamic nucleus and not the paraventricular hypothalamic nucleus. Endocrinology 2001;142:4236–4243.
  21. Germain D: Thyroid hormone metabolism; in Degroot LJ, Jameson JL (eds): Endocrinology. New York, Saunders, 2001.
  22. Kyrkouli SE, Stanley BG, Seirafi RD, Leibowitz SF: Stimulation of feeding by galanin: Anatomical localization and behavioral specificity of this peptide’s effects in the brain. Peptides 1990;11:995–1001.
  23. Mclaughlin PJ, Kilk K, Soomets U, Barfatai T, Langel U, Robinson JK: Peptide nucleic acid antisense oligomers differentiate the involvement of GALR1 and GALR2 receptor subtypes in feeding and working memory. Society for Neuroscience, 2001, abstract.
  24. Clark JT, Kalra PS, Crowley WR, Kalra SP: Neuropeptide Y and human pancreatic polypeptide stimulate feeding behavior in rats. Endocrinology 1984;115:427–429.
  25. Lambert PD, Couceyro PR, McGirr KM, Dall Vechia SE, Smith Y, Kuhar MJ: CART peptides in the central control of feeding and interactions with neuropeptide Y. Synapse 1998;29:293–298.
  26. Baker RA, Herkenham M: Arcuate nucleus neurons that project to the hypothalamic paraventricular nucleus: Neuropeptidergic identity and consequences of adrenalectomy on mRNA levels in the rat. J Comp Neurol 1995;358:518–530.
  27. Matsumoto H, Noguchi J, Takatsu Y, Horikoshi Y, Kumano S, Ohtaki T, Kitada C, Itoh T, Onda H, Nishimura O, Fujino M: Stimulation effect of galanin-like peptide on luteinizing hormone-releasing hormone-mediated luteinizing hormone secretion in male rats. Endocrinology 2001;142:3693–3696.
  28. Billington CJ, Briggs JE, Grace M, Levine AS: Effects of intracerebroventricular injection of neuropeptide Y on energy metabolism. Am J Physiol 1991;260:R321–R327.
  29. Small CJ, Kim MS, Stanley SA, Mitchell JR, Murphy K, Morgan DG, Ghatei MA, Bloom SR: Effects of chronic central nervous system administration of agouti-related protein in pair-fed animals. Diabetes 2001;50:248–254.
  30. Shimada M, Tritos NA, Lowell BB, Flier JS, Maratos-Flier E: Mice lacking melanin-concentrating hormone are hypophagic and lean. Nature 1998;396:670–674.
  31. Ottlecz A, Snyder GD, McCann SM: Regulatory role of galanin in control of hypothalamic-anterior pituitary function. Proc Natl Acad Sci USA 1988;85:9861–9865.
  32. Menendez JA, Atrens DM, Leibowitz SF: Metabolic effects of galanin injections into the paraventricular nucleus of the hypothalamus. Peptides 1992;13:323–327.
  33. Jureus A, Cunningham MJ, McClain ME, Clifton DK, Steiner RA: Galanin-like peptide is a target for regulation by leptin in the hypothalamus of the rat. Endocrinology 2000;141:2703–2706.

Pay-per-View Options
Direct payment This item at the regular price: USD 38.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 26.50